 Celldex Therapeutics, Inc. Celldex or the Company CLDX, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30day option to purchase up to an additional 15 of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company. 